Nanomedicinal delivery approaches for therapeutic siRNA

International Journal of Pharmaceutics

Volumn 379, Issue 2, 2009, Pages 210-211

  Keller, Michael ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Formulation; Liposomes; Nanomedicine; Nanotechnology; RNAi; siRNA

Indexed keywords

ALN RSV 01; AMPHOTERICIN B LIPID COMPLEX; APOLIPOPROTEIN B; BEVASIRANIB; CISPLATIN; DAUNORUBICIN; DOXORUBICIN; I5NP; LIPOSOME; NANOPARTICLE; NAVELBINE; PF 4523655; PLATINUM 1,2 DIAMINOCYCLOHEXANE; PR 4523655; RANIBIZUMAB; RTP 801I 14; SIRNA 027; SMALL INTERFERING RNA; SPHINGOLIPID; STABLE NUCLEIC ACID LIPID PARTICLE; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE KIDNEY FAILURE; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; GENE SILENCING; HEAD AND NECK CANCER; HUMAN; NANOENCAPSULATION; NANOPHARMACEUTICS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA INTERFERENCE; SINGLE DRUG DOSE; SYSTEMIC MYCOSIS; VIRUS INFECTION;

ANIMALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; NANOMEDICINE; RNA, SMALL INTERFERING;

EID: 68949208581     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.03.038     Document Type: Review

References (26)

1. (1) http://www.tekmirapharm.com/Programs/Pipeline.asp
2. (2) http://www.antigenics.com/products/cancer/aroplatin/
3. (3) http://www.celsion.com/pipeline.cfm
4. (4) http://www.merck.com/finance/pipeline.swf
5. (5) http://www.alnylam.com/Programs-and-Pipeline/Programs/index.php
6. (6) http://clinicaltrials.gov/ct2/results?term=siRNA
7. Aleku M., Schulz P., Keil O., Santel A., Schaeper U., Dieckhoff B., Janke O., Endruschat J., Durieux B., Roder N., Loffler K., Lange C., Fechtner M., Mopert K., Fisch G., Dames S., Arnold W., Jochims K., Giese K., Wiedenmann B., Scholz A., and Kaufmann J. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3 inhibits cancer progression. Cancer Res. 68 (2008) 9788-9798
8. Cherry S. Genomic RNAi screening in Drosophila S2 cells: what have we learned about host-pathogen interactions?. Curr. Opin. Microbiol. 11 (2008) 262-270
9. De Souza E.B., Cload S.T., Pendergrast P.S., and Sah D.W.Y. Novel therapeutic modalities to address nondrugable protein interaction targets. Neuropsychopharmacology 34 (2009) 142-158
10. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
11. Elbashir S.M., Lendeckel W., and Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15 (2001) 188-200
12. Fenske D.B., and Cullis P.R. Liposomal nanomedicines. Expert Opin. Drug Del. 5 (2008) 25-44
13. Fire A., Xu S.Q., Montgomery M.K., Kostas S.A., Driver S.E., and Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391 (1998) 806-811
14. Hamilton A.J., and Baulcombe D.C. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 286 (1999) 950-952
15. Harrington K.J., Lewanski C.R., Northcote A.D., Whittaker J., Wellbank H., Vile R.G., Peters A.M., and Stewart J.S.W. Phase I-II study of pegylated liposomal cisplatin (SPI-077 (TM)) in patients with inoperable head and neck cancer. Ann. Oncol. 12 (2001) 493-496
16. Harrington K.J., Rowlinson-Busza G., Syrigos K.N., Vile R.G., Uster P.S., Peters A.M., and Stewart J.S.W. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clin. Cancer Res. 6 (2000) 4939-4949
17. Judge A., and MacLachlan I. Overcoming the innate immune response to small interfering RNA. Hum. Gene Ther. 19 (2008) 111-124
18. Judge A.D., Bola G., Lee A.C.H., and MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13 (2006) 494-505
19. Judge A.D., Sood V., Shaw J.R., Fang D., McClintock K., and MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23 (2005) 457-462
20. Morrissey D.V., Lockridge J.A., Shaw L., Blanchard K., Jensen K., Breen W., Hartsough K., Machemer L., Radka S., Jadhav V., Vaish N., Zinnen S., Vargeese C., Bowman K., Shaffer C.S., Jeffs L.B., Judge A., MacLachlan I., and Polisky B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23 (2005) 1002-1007
21. Muller-Hartmann H., Faust N., Kazinski M., and Kretzschmar T. High-throughput transfection and engineering of primary cells and cultured cell lines-an invaluable tool for research as well as drug development. Expert Opin. Drug Discov. 2 (2007) 1453-1465
22. Napoli C., Lemieux C., and Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 2 (1990) 279-289
23. Sioud M., and Sorensen D.R. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem. Biophys. Res. Commun. 312 (2003) 1220-1225
24. Vanderkrol A.R., Mur L.A., Beld M., Mol J.N.M., and Stuitje A.R. Flavonoid genes in petunia-addition of a limited number of gene copies may lead to a suppression of gene-expression. Plant Cell 2 (1990) 291-299
25. Wagner E. The silent (r)evolution of polymeric nucleic acid therapeutics. Pharm. Res. 25 (2008) 2920-2923
26. Zimmermann T.S., Lee A.C.H., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N., Harborth J., Heyes J.A., Jeffs L.B., John M., Judge A.D., Lam K., McClintock K., Nechev L.V., Palmer L.R., Racie T., Rohl I., Seiffert S., Shanmugam S., Sood V., Soutschek J., Toudjarska I., Wheat A.J., Yaworski E., Zedalis W., Koteliansky V., Manoharan M., Vornlocher H.P., and MacLachlan I. RNAi-mediated gene silencing in non-human primates. Nature 441 (2006) 111-114